Lead Product(s) : Sofosbuvir,Velpatasvir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ACTG Announces Publication of Pivotal Hepatitis C Study in Clinical Infectious Diseases
Details : ACTG 5360 is a combination of sofosbuvir which is an inhibitor of the HCV NS5B RNA-dependent RNA polymerase, whereas velpatasvir is an inhibitor of the HCV NS5A protein, both required for viral replication. Currently being studied for chronic hepatitis C...
Product Name : ACTG 5360
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 23, 2023
Lead Product(s) : Sofosbuvir,Velpatasvir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sofosbuvir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Researchers Identify Multiple Molecules tat Shut Down SARS-Cov-2 Polymerase Reaction
Details : Researchers at Columbia Engineering and the University of Wisconsin-Madison have identified a library of molecules that shut down the SARS-CoV-2 polymerase reaction. Five of these molecules are already FDA-approved for use in the treatment of other viral...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 30, 2020
Lead Product(s) : Sofosbuvir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
